Frazier Life Sciences Management’s Autolus Therapeutics AUTL Stock Holding History

Frazier Life Sciences Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.12M	Hold	4,447,910	–	–	0.16%	39
2026 Q1	$6.14M	Sell	4,447,910 -175,414	-4%	-$266K	0.16%	36
2025 Q4	$9.2M	Hold	4,623,324	–	–	0.25%	36
2025 Q3	$7.54M	Hold	4,623,324	–	–	0.23%	43
2025 Q2	$10.5M	Hold	4,623,324	–	–	0.42%	39
2025 Q1	$7.17M	Hold	4,623,324	–	–	0.33%	37
2024 Q4	$10.9M	Hold	4,623,324	–	–	0.45%	35
2024 Q3	$16.8M	Hold	4,623,324	–	–	0.67%	32
2024 Q2	$16.1M	Hold	4,623,324	–	–	0.75%	29
2024 Q1	$29.5M	Buy	4,623,324 +876,467	+23%	+$5.47M	1.24%	25
2023 Q4	$24.1M	Hold	3,746,857	–	–	1.29%	21
2023 Q3	$8.73M	Hold	3,746,857	–	–	0.58%	31
2023 Q2	$8.92M	Hold	3,746,857	–	–	0.53%	34
2023 Q1	$6.89M	Hold	3,746,857	–	–	0.5%	37
2022 Q4	$7.12M	Hold	3,746,857	–	–	0.44%	35
2022 Q3	$8.02M	Hold	3,746,857	–	–	0.62%	34
2022 Q2	$10.6M	Hold	3,746,857	–	–	1%	26
2022 Q1	$15.6M	Buy	+3,746,857	New	+$15.8M	1.33%	24

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Frazier Life Sciences Management's AUTL Position: Q2 2026 in Review

Frazier Life Sciences Management held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 4,447,910 shares worth $7.12M. The position accounts for 0.16% of the portfolio, ranked #39.

Frazier Life Sciences Management first reported a position in AUTL in Q1 2022 and has held it in 18 quarters since. The position peaked at $29.5M in Q1 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

Frazier Life Sciences Management held 4,447,910 shares of Autolus Therapeutics worth $7.12M as of Q2 2026.
Frazier Life Sciences Management left its Autolus Therapeutics share count unchanged in Q2 2026.
Autolus Therapeutics made up 0.16% of Frazier Life Sciences Management's portfolio in Q2 2026, its #39 holding.
Frazier Life Sciences Management first reported a position in Autolus Therapeutics in Q1 2022 and has held it in 18 quarters since.
Frazier Life Sciences Management's Autolus Therapeutics position peaked at $29.5M in Q1 2024.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.